Wockhardt’s board has approved a proposal to raise up to Rs 1,000 crore through a rights issue. The objective of the issue is to meet the company's financing needs for repayment of subordinated debt due, financing research and development initiatives and general corporate purposes, among others, permitted by law.
Wockhardt is a research based global pharmaceutical and Biotech Company headquartered in Mumbai, India.